Ian B. Li
Adele C. Oliva
Adele Oliva has been a healthcare investor for over 20 years and focuses on commercial stage medical technology, healthcare service, and specialty therapeutic investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing and the firm has since raised two funds and has over $500 million under management. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.
Forbes recognized Adele on its Midas List of top 100 technology investors worldwide and top 10 life science investors. Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.
Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Genoptix (acquired by NeoGenomics), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Greenbrook TMS, Homestead Smart Health Plans, Innovative Health, miraDry, Onkos Surgical, and TELA Bio.
Michael Koby co-founded 1315 Capital in 2014, after spending his entire career as a healthcare investor and operator, including experience with more than 25 growth equity investments. Prior to founding 1315 Capital, Michael was a Managing Director at Palm Ventures, a private-equity focused family office where he led all healthcare investing. While at Palm, Michael led investments in Enigma Diagnostics, Axcentria Pharmaceuticals, and JDS Therapeutics. He currently serves on the boards of Biocoat, CHC Solutions, JDS Therapeutics, and Misonix.
Before Palm Ventures, Michael spent over a decade as an investor, including before and after business school, at Galen Partners, a healthcare growth equity investment firm. He also held business development roles at Novoste Corporation and Medtronic, Inc. Michael started his career as a healthcare investment banking analyst at Dillon, Read & Co.
Michael received a BSc from Cornell University and an MBA in Healthcare Management from The Wharton School.
Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of ProSciento, Reaction Biology, Restorative Therapies, and Verogen. Matthew also serves on the Board of Directors of Life Sciences Pennsylvania.
Matthew has over a decade of growth stage investing experience with a focus on the specialty pharmaceutical and medical technology sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners. Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financings over the course of his career.
Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.
Edward Chan joined 1315 Capital in 2016 after spending 5 years at NaviMed Capital. Prior to joining NaviMed Capital, Edward was part of the healthcare investment team at Siemens Venture Capital. Edward also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Edward started his career developing and commercializing a molecular diagnostic product at a venture backed company.
Edward has served on the board or as a board observer at the following companies: Genoptix (acquired by NeoGenomics), Centurion Service Group (acquired by TRIMEDX), Greenbrook TMS, and CenterPointe Behavioral Health System. He currently serves on the board of Homestead Smart Health Plans and Interpace Biosciences.
Edward received a BSc in Biomedical Engineering from Johns Hopkins University and an MBA in Healthcare Management and Finance from the Wharton School at the University of Pennsylvania.
Ian B. Li
Ian Li joined 1315 Capital in 2015, after spending four years as a healthcare management and strategy consultant, most recently at Capgemini Consulting. Ian has worked with commercial executives from top pharmaceutical companies on implementing large scale strategic initiatives, with projects spanning market access, product launch, healthcare reform readiness, and engagement of integrated health network (IHN) customers. Prior to consulting, Ian also had experience working at Stryker Orthopaedics in the quality engineering department. He currently serves on the board of miraDry.
Ian received a BSc in Biomedical Engineering from Duke University, with a minor in Economics.
Craig Matturro joined 1315 Capital in 2016 after two years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.
Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.
Jordan Brown joined 1315 Capital in 2020. Previously, Jordan worked on the investment team at Northwell Ventures, where she managed investments in several early-stage HIT, medical technology and healthcare services businesses. In this role, she was actively involved in sourcing, due diligence and investment, as well as support of portfolio companies. Jordan also has experience in biotechnology M&A. She began her career at Piper Sandler (fka Piper Jaffray) in their Healthcare Investment Banking group.
Jordan received a BA, magna cum laude, from the University of Pennsylvania, where she competed in D1 Track & Field, and an MBA from the Wharton School at the University of Pennsylvania, where she was awarded a Joseph Wharton Fellowship.
Ryan Kraus joined 1315 Capital in 2020. Previously, he worked as an Analyst at MTS Health Partners, focusing on M&A and financing transactions across the pharmaceutical, biotechnology, and healthcare services subsectors. Prior to MTS, Ryan worked at Pacira BioSciences in Corporate Strategy and Business Development.
Ryan received a BS in Finance, summa cum laude, from Rutgers University.
Business Development Associate
Jamie Richardson joined 1315 Capital in 2020, after spending over three years at ProMedica, most recently as an Investment Associate. In this role, Jamie worked on numerous debt and equity financings of innovative healthcare companies and led the due diligence, investment committee approval and transaction process for companies in the ProMedica Ventures portfolio. He also supported portfolio companies and worked with entrepreneurs to help their companies with business and financial strategy throughout the life of the investment.
Jamie received a BA and MBA in Finance from the University of Toledo where he represented the Varsity Golf Team as an NCAA Division 1 Student Athlete.
Chief Financial Officer & Chief Compliance Officer
Brian Schwenk joined 1315 Capital in 2014, and has 14 years of experience in private equity and public accounting. Since 2012, Brian has worked with Adele Oliva at Quaker Partners as Chief Financial Officer. His roles at 1315 Capital include oversight of accounting, treasury, financial reporting, and performance analysis as well as human resources, investor relations, information technology, risk management, and compliance.
Brian also spent nearly 7 years at an affiliate of Quaker, Independence Capital Partners, most recently as Senior Controller. Earlier in his career, Brian worked for American Express Tax & Business Services, Stout Causey Consulting, and Arthur F. Bell, Jr. & Associates as an audit associate.
Brian received a BA in management with a concentration in Accounting from Gettysburg College and an MBA with a concentration in Accounting from Loyola College in Maryland.
Senior Financial Accountant
Jacqueline Akpan, CPA joined 1315 Capital in 2018 and has three years of experience in public accounting. Prior to joining 1315 Capital, Jacqueline worked at KPMG LLP as an auditor, where she audited companies within the financial services industry. Her roles at 1315 Capital include assisting the CFO with accounting, reporting and administration of investment vehicles.
Jacqueline received a BBA from Temple University, with a major in Accounting and a minor in Finance.
Ernie Biczak, M.D.
Operating Team Member
Ernie Biczak is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. Ernie was formerly Chief Operating Officer and Executive Vice President of Sales & Marketing at NovaSom. Prior to NovaSom, Ernie held various executive positions in the Medical Affairs and Marketing Departments of ESP Pharma, ESPRIT Pharma, and EKR Pharma, and has also served as a consultant to The Medicines Company, Incline Therapeutics, and Cornerstone Therapeutics. Prior to that, Ernie practiced emergency medicine and also worked with St. Barnabas HealthCare System (now Barnabas Health) in New Jersey as Vice President of Physician Practices, where he was a liaison between the healthcare system and their employed physicians. Ernie was also a co-founder of Immediate Medical Care Centers (IMCC), some of the first urgent care centers in New Jersey, where he practiced medicine for 16 years. Prior to IMCC, Ernie helped develop the Emergency Medicine Residency at Morristown Memorial Hospital in Morristown, New Jersey where he also served as Assistant Emergency Department Director for 3 years.
Ernie received his M.D. degree from Rutgers Medical School, and completed his residency in Emergency Medicine at the Michigan State University Affiliated Hospitals where he also held the position of Chief Resident.
Operating Team Member
Tim Einwechter is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. Tim is co-founder and Chief Financial Officer of Innovative Health, a medical device reprocessing company focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, he was co-founder and Chief Financial Officer for Intralign. Tim was also Chief Financial Officer of Alliance Medical, and later Ascent Healthcare Solutions (acquired by Stryker for $525 million). Prior to joining Alliance Medical, Tim was Chief Operating Officer of Healthworks Managed Care Services, a private company engaged in the provision of rehabilitation services. He also spent time as Chief Financial Officer of Dynacare Health Services, a publicly traded health services company engaged in the business of providing home healthcare and laboratory diagnostic services, and before that tenured as a Vice President of Versa-Care, a company engaged in the provision of accommodation for senior citizens. Tim also serves on the Board of Directors for CHC Solutions.
Tim was named Arizona’s 2010 Private Company CFO of the Year by the Financial Executives Institute.
Tim received an Honors BA in Business Administration from Wilfrid Laurier University and is a Chartered Accountant.
Operating Team Member
Rick Ferreira is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. Rick is a serial entrepreneur and currently President & CEO of Innovative Health, a medical device reprocessing company he co-founded focused on cost containment, particularly in the cardiology space. Prior to Innovative Health, Rick was President & CEO of Intralign, a company he co-founded to help hospitals and surgeons reduce costs and improve efficiencies around joint replacement surgery. Prior to Intralign, Rick founded Alliance Medical in 1997, the first major medical device reprocessing company. Alliance Medical merged with Vanguard Medical Concepts in 2005 to become Ascent Healthcare Solutions (acquired by Stryker for $525 million). Rick previously served on the Board of Directors of Centurion Service Group (acquired by Trimedx, LLC in 2020).
Rick started his first company, International Managed Healthcare, a Canadian company engaged in the provision of rehabilitation services, in 1990. The company was sold to Liberty Mutual Insurance in 1994. Rick began his career with the Royal Bank of Canada.
Rick received a BA in Business Administration from the University of Toronto.
Operating Team Member
Antony Koblish is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. Antony is a medical device entrepreneur with 25 years of experience in healthcare. Antony is co-founder and President & CEO of TELA Bio, a biosurgical reconstruction company based in Malvern, Pennsylvania. Prior to founding TELA Bio, Antony was President and CEO of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as CEO of Orthovita from 2002 to 2011, Antony created significant company value, growing valuation from $30 million to a $316 million sale to Stryker Corporation in May 2011. Antony is a skilled leader with a proven track record in driving sales growth, building a robust product pipeline, establishing world-class commercial operations, and instilling clinical & manufacturing quality.
Antony is also a co-founder and currently serves as Chairman of the Board of Onkos Surgical, a surgical oncology company, and on the Board of Directors for miraDry.
Antony received a BSc in Mechanical Engineering from Worcester Polytechnic Institute, and an MS in Mechanical Engineering & Applied Mechanics from the University of Pennsylvania.
Operating Team Member
Greg Stokes is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. Greg was formerly Chief Executive Officer of NovaSom, and has 25 years of pharmaceutical and medical device experience, having worked in sales, marketing, and business development. Prior to NovaSom, he co-founded and served as Executive Vice President of Business Development at Oceana Therapeutics (acquired by Salix for $300 million). Previous positions include co-founder, President and Chief Operating Officer of Esprit Pharma, Inc. (acquired by Allergan for $360 million), Vice President of Corporate Development for ESP Pharma (acquired by Protein Design Labs for $500 million), and Director of Business Development with Shire.
Greg received a BA from University of Pennsylvania, JD from Rutgers University and MBA from Rutgers University.
Operating Team Member
Paul Touhey is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm with over $500 million under management. He is the former President / CEO and member of the Board of Directors of Fujirebio Diagnostics, Inc. (FDI), a premier cancer diagnostics company. Paul has more than 30 years of industry experience.
Paul joined FDI (formerly Centocor Diagnostics) in 1985, where he held a variety of positions, including Senior Vice President of Operations. Prior to FDI and Centocor, Paul worked for Johnson & Johnson in a variety of positions with increasing levels of responsibility and management.
Paul is the past Chairman of the Board of the Medical Device Manufacturers Association (MDMA), a national trade association representing the entrepreneurial sector of the medical device industry in the United States. He also serves on the Board of the University City Science Center. Paul established the Companies of Caring campaign with the Community Volunteers in Medicine, a Chester County charity focusing on providing medical care to the uninsured.
Paul serves on the Board of Directors of Onkos Surgical, and previously served on the Board of Directors of Invisible Sentinel (acquired by BioMérieux in 2019), Genoptix (acquired by NeoGenomics in 2018) and Orthovita, Inc., a publicly traded orthobiologics company (acquired by Stryker in 2011).
Paul received a BA in Political Science from Temple University.